Windtree Therapeutics, Inc. Additional Paid In Capital

Additional Paid In Capital of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Additional Paid In Capital growth rates and interactive chart.


Highlights and Quick Summary

  • Additional Paid In Capital for the quarter ending June 29, 2020 was $788 Million (a 3.0% increase compared to previous quarter)
  • Year-over-year quarterly Additional Paid In Capital increased by 7.34%
  • Annual Additional Paid In Capital for 2019 was $763 Million (a 4.7% increase from previous year)
  • Annual Additional Paid In Capital for 2018 was $729 Million (a 18.26% increase from previous year)
  • Annual Additional Paid In Capital for 2017 was $616 Million (a 3.94% increase from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Additional Paid In Capital of Windtree Therapeutics, Inc.

Most recent Additional Paid In Capitalof WINT including historical data for past 10 years.

Interactive Chart of Additional Paid In Capital of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Additional Paid In Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $787.71 $764.79
2019 $763.1 $733.84 $731.9 $730.16 $763.07
2018 $728.78 $620.32 $619.34 $616.61 $728.78
2017 $616.25 $605.18 $605.0 $604.68 $616.25
2016 $592.89 $592.26 $591.53 $591.15 $592.89
2015 $590.49 $589.9 $547.4 $546.97 $590.49
2014 $546.26 $545.31 $544.22 $543.2 $546.26
2013 $541.42 $476.7 $475.81 $459.84 $541.42
2012 $455.4 $453.98 $453.29 $452.68 $455.4
2011 $401.71 $400.88 $400.61 $400.19 $401.71
2010 $385.52 $383.67 $392.16 $380.57 $385.52

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.